{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:26:31Z","timestamp":1787635591969,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00280-019-03789-3","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T04:23:24Z","timestamp":1550204604000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-3275","authenticated-orcid":false,"given":"Ian Joseph","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Kollender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Fenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Konen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Bar-Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Issakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meora","family":"Feinmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smadar","family":"Avigad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifra","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"3789_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/1097-0142(197611)38:5<1925::AID-CNCR2820380510>3.0.CO;2-J","volume":"38","author":"N Jaffe","year":"1976","unstructured":"Jaffe N, Paed D, Traggis D, Salian S, Cassady JR (1976) Improved outlook for Ewing\u2019s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38:1925\u20131930","journal-title":"Cancer"},{"key":"3789_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.1990.8.10.1664","volume":"8","author":"ME Nesbit Jr","year":"1990","unstructured":"Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing\u2019s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664\u20131674","journal-title":"J Clin Oncol"},{"key":"3789_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694\u2013701","journal-title":"N Engl J Med"},{"key":"3789_CR4","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036\u20133046","journal-title":"J Clin Oncol"},{"key":"3789_CR5","doi-asserted-by":"crossref","unstructured":"Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E et al (2018) Improved outcome in local Ewing Sarcoma with an intensified pilot treatment protocol SCMCIE94. J Ped Hematol Oncol 2018 (in press)","DOI":"10.1097\/MPH.0000000000001384"},{"key":"3789_CR6","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-10-3069","volume":"17","author":"S Ash","year":"2011","unstructured":"Ash S, Luria D, Cohen IJ, Goshen Y, Toledano H, Issakov J al (2011) Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin Cancer Res 17:2900\u20132907","journal-title":"Clin Cancer Res"},{"key":"3789_CR7","volume-title":"BMDP statistical software","author":"WJ Dixon","year":"1993","unstructured":"Dixon WJ (1993) BMDP statistical software. University of California Press, Los Angeles"},{"key":"3789_CR8","first-page":"49;1221","volume":"110","author":"G Rosen","year":"1982","unstructured":"Rosen G, Caparros B, Hurvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of post operative chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 110:49;1221\u20131230","journal-title":"Cancer"},{"key":"3789_CR9","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"FW Abdul-Karim","year":"2012","unstructured":"Abdul-Karim FW, Buaer TW, Kilpatrick SC, Raymond KA, Siegal GP,. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE et al (2012) Recommendations for the reporting of bone tumors. Hum Path (2004)35; 1173-1178.9. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol 30:4148\u20134154","journal-title":"J Clin Oncol"},{"key":"3789_CR10","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1200\/JCO.2008.19.1478","volume":"27","author":"L Granowetter","year":"2009","unstructured":"Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M et al (2009) Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children\u2019s Oncology Group Study. J Clin Oncol 27:2536\u20132541","journal-title":"J Clin Oncol"},{"key":"3789_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ijrobp.2017.08.020","volume":"99","author":"SA Ahmed","year":"2017","unstructured":"Ahmed SA, Randall RL, Dubois SG, Harmsen WS, Krailo M, Marcus KJ et al (2017) Identification of patients with localized ewing sarcoma at higher risk for local failure: a report from the childrens oncology group. Int J Radiat Oncol Biol Phys 99:1286\u20131294","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3789_CR12","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1097-0142(19810501)47:9<2204::AID-CNCR2820470916>3.0.CO;2-A","volume":"46","author":"G Rosen","year":"1981","unstructured":"Rosen G, Caparros B, Nirenbirg A, Marcove RC, Huvos AG, Kosloff C, Lane J, Murphy ML (1981) Ewing sarcoma: ten year experience with adjuvant chemotherapy. Cancer 46:2204\u20132213","journal-title":"Cancer"},{"key":"3789_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-018-0093-y","volume":"8","author":"J Whelan","year":"2008","unstructured":"Whelan J, Hackshaw A, McTienan A, Grimer R, Spooner D, Bate J et al (2008) Survival is influence by approaches to local treatmrent of Ewing sarcoma within an international randomised controlled trial:analysis of EICESS-92. Clin Sarcoma Res 8:6. \n                    https:\/\/doi.org\/10.1186\/s13569-018-0093-y","journal-title":"Clin Sarcoma Res"},{"key":"3789_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ijrobp.2004.04.006","volume":"60","author":"MJ Krasin","year":"2004","unstructured":"Krasin MJ, Rodriguez-Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, Kun LE (2004) Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 60:830\u2013838","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3789_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0039-6060(05)80235-1","volume":"1","author":"DC Brown","year":"1995","unstructured":"Brown DC, Purushotham AD, Birnie GD, George WD (1995) Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery 1:96\u2013101","journal-title":"Surgery"},{"key":"3789_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0959-8049(00)00028-9","volume":"36","author":"I Elomaa","year":"2000","unstructured":"Elomaa I, Blomqvist CP, Saeter G, Akerman M, Stenwig E, Wiebe T, Bj\u00f6rk O, Alveg\u00e5rd TA (2000) Five-year results in Ewing\u2019s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 36:875\u2013880","journal-title":"Eur J Cancer"},{"key":"3789_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2106\/JBJS.H.00449","volume":"91","author":"H Imran","year":"2009","unstructured":"Imran H, Enders E, Krailo M, Sim F, Okuno S, Hawkins D et al (2009) Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Jt Surg Am 91:604\u2013612","journal-title":"J Bone Jt Surg Am"},{"key":"3789_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/08880019109033447","volume":"8","author":"IJ Cohen","year":"1991","unstructured":"Cohen IJ, Loven D, Shoenfeld T, Sandbank J, Kaplinsky C, Yaniv Y, Jaber L, Zaizov R (1991) Dactinomycin potentiation of radiation pneumonitis: a forgotten interaction. Ped Hematol Oncol 8:187\u2013192","journal-title":"Ped Hematol Oncol"},{"key":"3789_CR19","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/1097-0142(19810501)47:9<2302::AID-CNCR2820470933>3.0.CO;2-K","volume":"47","author":"GJ D\u2019Angio","year":"1981","unstructured":"D\u2019Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V et al (1981) The treatment of Wilms\u2019 tumor: results of the Second National Wilms\u2019 Tumor study. Cancer 47:2302\u20132311","journal-title":"Cancer"},{"key":"3789_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","volume":"11","author":"RJ Packer","year":"1993","unstructured":"Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low grade glioma of childhood. J Clin Oncol 11:850\u2013856","journal-title":"J Clin Oncol"},{"key":"3789_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa035153","volume":"351","author":"S Lipshultz","year":"2004","unstructured":"Lipshultz S, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145\u2013153","journal-title":"N Engl J Med"},{"key":"3789_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","volume":"25","author":"CK Tebbi","year":"2007","unstructured":"Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS et al (2007) Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease. J Clin Oncol 25:493\u2013500","journal-title":"J Clin Oncol"},{"key":"3789_CR23","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","volume":"65","author":"RS Cvetkovi\u0107","year":"2006","unstructured":"Cvetkovi\u0107 RS, Scott LJ (2006) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005\u20131024","journal-title":"Drugs"},{"key":"3789_CR24","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/cncr.30589","volume":"123","author":"DR Reed","year":"2017","unstructured":"Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS et al (2017) Treatment pathways of bone sarcoma in children, adolescents, and young adults. Cancer 123:2206\u20132218","journal-title":"Cancer"},{"key":"3789_CR25","doi-asserted-by":"publisher","unstructured":"Reichardt P, Tabone M, Mora J et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity:re-evaluating the European labeling. Future Oncol. \n                    https:\/\/doi.org\/10.2217\/fon-2018-0210","DOI":"10.2217\/fon-2018-0210"},{"key":"3789_CR26","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD,et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana Farber 91 \u2013 01 acute lymphoblastic leukemia protocol. J Clin Oncol 20:1677\u20131682","journal-title":"J Clin Oncol"},{"key":"3789_CR27","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","volume":"15","author":"SR Patel","year":"1997","unstructured":"Patel SR, Yadhan-Raj S, Papadopolous N, Plager C, Burgess A, Hayes C et al (1997) High dose ifosfamide in bone and soft tissue sarcomas: results of phase II and piolot studies-dose response and schedule dependence. J Clin Oncol 15:2378\u20132384","journal-title":"J Clin Oncol"},{"key":"3789_CR28","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/cncr.22964","volume":"110","author":"J Morales-Arias","year":"2007","unstructured":"Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K et al (2007) Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110:1568\u20131577","journal-title":"Cancer"},{"key":"3789_CR29","unstructured":"EURO-E.W.I.N G. Study Committee (1999) EURO-E.W.I.N.G. 99 Study Manual\u2014EUROpean Ewing Tumor Initiative of National Groups Ewing Tumor Studies 1999. \n                    https:\/\/www.childrensoncologygroup.org\/index.php\/aews0331\n                    \n                  . Accessed 22 February 2006"},{"key":"3789_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/pbc.21618","volume":"51","author":"PJ Leavey","year":"2008","unstructured":"Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J et al, Children\u2019s Oncology Group (2008) Prognostic factors for patients with Ewing Sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children\u2019s Oncology group. Blood Cancer 51:334\u2013338","journal-title":"Blood Cancer"},{"key":"3789_CR31","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","volume":"23","author":"LA Barker","year":"2005","unstructured":"Barker LA, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing\u2019s Sarcoma Family of tumors. J Clin Oncol 23:4354\u20134362","journal-title":"J Clin Oncol"},{"key":"3789_CR32","first-page":"31103119","volume":"36","author":"J Whelan","year":"2018","unstructured":"Whelan J, Le Delay MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N et al (2018) High-dose chemotherapy and blood autologous stem -cell rescue compared with standard chemotherapy in localized high-risk Ewing Sarcoma: results of euro-E.W.I.N.G99 and Ewing\u20142008. J Clin Oncol 36:31103119","journal-title":"J Clin Oncol"},{"key":"3789_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1999.17.1.180","volume":"17","author":"NM Marina","year":"1999","unstructured":"Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA et al (1999) Chemotherapy dose-intensification for pediatric patients with Ewing\u2019s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children\u2019s Research Hospital. J Clin Oncol 17:180\u2013190","journal-title":"J Clin Oncol"},{"key":"3789_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2000.18.1.4","volume":"18","author":"G Bacci","year":"2000","unstructured":"Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing\u2019s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4\u201311","journal-title":"J Clin Oncol"},{"key":"3789_CR35","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.2003.10.033","volume":"21","author":"EA Kolb","year":"2003","unstructured":"Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Heley JH, LaQualglia MP et al (2003) Long-term event-free survival after intensive chemotherapy for Ewing\u2019s family of tumors in children and young adults. J Clin Oncol 21:3423\u20133430","journal-title":"J Clin Oncol"},{"key":"3789_CR36","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1200\/JCO.2007.13.1292","volume":"25","author":"C Swartz","year":"2007","unstructured":"Swartz C, Constine LS, London WB, Sposto R, Friedman DL, Tebbi CK et al (2007) Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkins disease: a claim without evidence In reply. J Clin Oncol 25:4690\u20134691","journal-title":"J Clin Oncol"},{"key":"3789_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mpo.2950160511","volume":"16","author":"JH Silber","year":"1988","unstructured":"Silber JH, Kaixer H (1988) Marginal analysis applied to the dose-response curve. Med Pediatr Oncol 16:344\u2013348","journal-title":"Med Pediatr Oncol"},{"key":"3789_CR38","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","volume":"15","author":"SR Patel","year":"1997","unstructured":"Patel SR, Vadhan-Raj S, Papadopolous N, Plager MA, Burgess A, Hays S, Benjamin RS (1997) High dose Ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies\u2014dose-response and schedule dependence. J Clin Oncol 15:2378\u20132384","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03789-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:16:48Z","timestamp":1581707808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03789-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3789"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03789-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"1 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of our center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}